HK Stock Movement | PEGBIO CO-B (02565) Surges Nearly 15% at Open as Core Product PB-119 Receives NDA Approval

Stock News11-17

PEGBIO CO-B (02565) opened sharply higher by nearly 15%, rising 14.94% to HK$72.7 by the time of writing, with a turnover of HK$1.1269 million. The surge follows the company's announcement on November 14 that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for its core product PB-119.

PegDaCare® (PB-119) is a next-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by the company, administered once weekly. The product has been designated as a national Class 1 innovative drug under China's "Major New Drug Innovation" initiative.

Clinical trials from Phase I to Phase III have demonstrated that PB-119 achieves an optimal balance between effective blood glucose control and favorable tolerability, offering a high-efficacy and safe treatment option for Chinese patients with type 2 diabetes. Additionally, PB-119 significantly improves β-cell function and provides comprehensive management of blood pressure, lipids, and body weight, delivering holistic benefits beyond glycemic control.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment